Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding

References

• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology46(4), 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun.6(5), 375–387 (2005).
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Armstrong H, Rice GP et al. A population-based study of multiple sclerosis in twins: update. Ann. Neurol.33(3), 281–285 (1993).
   PubMed Web of Science ®Google Scholar
• Herrera BM, Ebers GC. Progress in deciphering the genetics of multiple sclerosis. Curr. Opin. Neurol.16(3), 253–258 (2003).
   PubMedGoogle Scholar
• Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature377(6545), 150–151 (1995).
   PubMed Web of Science ®Google Scholar
• Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain119(Pt 2), 449–455 (1996).
   PubMedGoogle Scholar
• Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol.59(3), 499–503 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Cesari C, Saniger MM, Sotelo J. Frequent association of multiple sclerosis with varicella and zoster. Acta Neurol. Scand.112(6), 417–419 (2005).
   PubMed Web of Science ®Google Scholar
• Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev. Med. Virol.15(3), 179–211 (2005).
   PubMed Web of Science ®Google Scholar
• Sundstrom P, Juto P, Wadell G et al. An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology62(12), 2277–2282 (2004).
   PubMed Web of Science ®Google Scholar
• Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol.105(12), 1296–1299 (1998).
   PubMedGoogle Scholar
• Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology55(6), 848–854 (2000).
   PubMed Web of Science ®Google Scholar
• Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch. Neurol.62(9), 1362–1365 (2005).
   PubMed Web of Science ®Google Scholar
• Zorzon M, Zivadinov R, Bosco A et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult. Scler.5(6), 418–427 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt EZ, Hofmann P, Niederwieser G, Kapfhammer HP, Bonelli RM. Sexuality in multiple sclerosis. J. Neural Transm.112(9), 1201–1211 (2005).
   PubMed Web of Science ®Google Scholar
• Pretta S, Ferrero S, Ragni N (and MS-IVF Study Group). Ovulation induction and in vitro fertilization in women with multiple sclerosis. Proceedings of the 22nd Annual Meeting of the European Society of Human Reproduction and Embryology. Prague, Czech Republic. Hum. Reprod.21(Suppl. 1), I145 (2006).
   Google Scholar
• Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain118(Pt 1), 253–261 (1995).
   PubMed Web of Science ®Google Scholar
• Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology169(1), 117–122 (1988).
   PubMedGoogle Scholar
• Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J. Magn. Reson. Imaging10(3), 477–484 (1999).
   PubMed Web of Science ®Google Scholar
• Leyendecker JR, Gorengaut V, Brown JJ. MR imaging of maternal diseases of the abdomen and pelvis during pregnancy and the immediate postpartum period. Radiographics24(5), 1301–1316 (2004).
   Google Scholar
• Roullet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, Marteau R. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J. Neurol. Neurosurg. Psychiatry56(10), 1062–1065 (1993).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med.339(5), 285–291 (1998).
   PubMed Web of Science ®Google Scholar
• Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain127(Pt 6), 1353–1360 (2004).
   PubMed Web of Science ®Google Scholar
• Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: the children of PRIMS. Clin. Neurol. Neurosurg.108(3), 266–270 (2006).
   Google Scholar
• Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology65(12), 1961–1963 (2005).
   PubMed Web of Science ®Google Scholar
• Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurol. Scand.183, 51–54 (2006).
   Google Scholar
• Weinshenker BG, Hader W, Carriere W, Baskerville J, Ebers GC. The influence of pregnancy on disability from multiple sclerosis: a population-based study in Middlesex County, Ontario. Neurology39(11), 1438–1440 (1989).
   PubMed Web of Science ®Google Scholar
• Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler.11(4), 425–432 (2005).
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Barnes D, Filippini G et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur. J. Neurol.12(12), 939–946 (2005).
   PubMed Web of Science ®Google Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology62(6), 385–392 (2000).
   PubMedGoogle Scholar
• Panitch H, Miller A, Paty D, Weinshenker B. Interferon β-1b in secondary progressive MS: results from a 3-year controlled study. Neurology63(10), 1788–1795 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobs L, Rudick R, Simon J. Extended observations on MS patients treated with IM interferon-β1a (Avonex): implications for modern MS trials and therapeutics. J. Neuroimmunol.107(2), 167–173 (2000).
   PubMedGoogle Scholar
• Piper JM, Wen TT, Xenakis EM. Interferon therapy in primary care. Prim. Care Update Ob. Gyns.8(4), 163–169 (2001).
   Google Scholar
• Arnason BG. Long-term experience with interferon β-1b (betaferon) in multiple sclerosis. J. Neurol.252(Suppl. 3), 28–33 (2005).
   Google Scholar
• Patti F, Pappalardo A, Florio C et al. Effects of interferon β-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol. Scand.113(4), 241–247 (2006).
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Sorensen PS, Christensen T et al. A randomized study of two interferon-β treatments in relapsing–remitting multiple sclerosis. Neurology66(7), 1056–1060 (2006).
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N. Engl. J. Med.354(9), 942–955 (2006).
   PubMed Web of Science ®Google Scholar
• Challier JC, Guerre-Millo M, Nandakumaran M, Gerbaut L, d’Athis P. Clearance of compounds of different molecular size in the human placenta in vitro. Biol. Neonate48(3), 143–148 (1985).
   PubMedGoogle Scholar
• Waysbort A, Giroux M, Mansat V, Teixeira M, Dumas JC, Puel J. Experimental study of transplacental passage of α interferon by two assay techniques. Antimicrob. Agents Chemother.37(6), 1232–1237 (1993).
   PubMed Web of Science ®Google Scholar
• Pons JC, Lebon P, Frydman R, Delfraissy JF. Pharmacokinetics of interferon-α in pregnant women and fetoplacental passage. Fetal Diagn. Ther.10(1), 7–10 (1995).
   PubMed Web of Science ®Google Scholar
• Biogen. Avonex® (Interferon β 1-a). Product monograph, 1998.
   Google Scholar
• Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon β-1a in patients with multiple sclerosis. Neurology65(6), 802–806 (2005).
   PubMed Web of Science ®Google Scholar
• Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of β interferon therapy in pregnancy: a longitudinal cohort. Neurology65(6), 807–811 (2005).
   PubMed Web of Science ®Google Scholar
• Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev.1, CD004678 (2004).
   Google Scholar
• Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol.4(9), 567–575 (2005).
   PubMed Web of Science ®Google Scholar
• Coyle PK, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone1). Proceedings of the 55th Annual Meeting of the American Academy of Neurology Honolulu, Hawaii, USA. Neurology60(5 Suppl. 1), A60 (2003).
   Web of Science ®Google Scholar
• Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov.4(6), 510–518 (2005).
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst. Rev. 2:CD003208 (2004).
   Google Scholar
• Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am. J. Med.88(6), 589–592 (1990).
   PubMed Web of Science ®Google Scholar
• Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet. Gynecol.99(4), 599–602 (2002).
   PubMed Web of Science ®Google Scholar
• Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am. J. Med. Genet.86(3), 237–241 (1999).
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing–remitting multiple sclerosis. Neurology41(1), 20–55 (1991).
   PubMed Web of Science ®Google Scholar
• Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R. Azathioprine and interferon β (1a) in relapsing–remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur. Neurol.51(1), 15–20 (2004).
   PubMed Web of Science ®Google Scholar
• Pulicken M, Bash CN, Costello K et al. Optimization of the safety and efficacy of interferon β 1b and azathioprine combination therapy in multiple sclerosis. Mult. Scler.11(2), 169–174 (2005).
   PubMed Web of Science ®Google Scholar
• Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am. J. Obstet. Gynecol.115(8), 1100–1106 (1973).
   PubMed Web of Science ®Google Scholar
• Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am. J. Obstet. Gynecol.97(3), 387–394 (1967).
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus10(3), 152–153 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch. Gynecol. Obstet.270(2), 79–85 (2004).
   PubMedGoogle Scholar
• Radomski JS, Ahlswede BA, Jarrell BE et al. Outcomes of 500 pregnancies in 335 female kidney, liver, and heart transplant recipients. Transplant Proc.27(1), 1089–1090 (1995).
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev. 4: CD002127 (2005).
   Google Scholar
• Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet360(9350), 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology63(12 Suppl. 6), S28–S32 (2004).
   PubMed Web of Science ®Google Scholar
• Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J. Neurol. Sci.206(2), 203–208 (2003)
   PubMed Web of Science ®Google Scholar
• Shenkenberg TD, Von Hoff DD. Possible mitoxantrone-induced amenorrhea. Cancer Treat. Rep.70(5), 659–661 (1986).
   PubMedGoogle Scholar
• Edan G, Brochet B, Clanet M et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Proceedings of the 56th Annual Meeting of the American Academy of Neurology San Francisco, California, USA. Neurology62(Suppl. 5), A493 (2004).
   Google Scholar
• Lemez P, Urbanek V. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma52(5), 398–401 (2005).
   Google Scholar
• Goffette S, van Pesch V, Vanoverschelde JL, Morandini E, Sindic CJ. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J. Neurol.252(10), 1217–1222 (2005).
   PubMed Web of Science ®Google Scholar
• Ghalie RG, Edan G, Laurent M et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology59(6), 909–913 (2002).
   PubMed Web of Science ®Google Scholar
• Novoselac AV, Reddy S, Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia18(9), 1561–1562 (2004).
   PubMed Web of Science ®Google Scholar
• Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult. Scler.10(4), 472–474 (2004).
   PubMed Web of Science ®Google Scholar
• Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst. Rev. 4: CD002936 (2003).
   Google Scholar
• Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology63(12 Suppl. 6), S47–S54 (2004).
   PubMed Web of Science ®Google Scholar
• Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J. Neurol.243(1), 25–28 (1996).
   PubMedGoogle Scholar
• Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult. Scler.6(Suppl. 2), S18–S20 (2000).
   Google Scholar
• Achiron A, Kishner I, Dolev M et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J. Neurol.251(9), 1133–1137 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar AR, Hale TW, Mock RE. Transfer of interferon α into human breast milk. J. Hum. Lact.16(3), 226–228 (2000).
   PubMedGoogle Scholar
• Farrell R, Heaney D, Giovannoni G. Emerging therapies in multiple sclerosis. Expert Opin. Emerg. Drugs10(4), 797–816 (2005).
   PubMedGoogle Scholar
• Kappos L, Achtnichts L, Dahlke F et al. Genomics and proteomics: role in the management of multiple sclerosis. J. Neurol.252(Suppl. 3), 21–27 (2005).
   Google Scholar